CellaVision AB (publ)

LSE:0MR5 Stock Report

Market Cap: SEK 5.0b

CellaVision Valuation

Is 0MR5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0MR5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 318.75
Fair Value
35.4% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: 0MR5 (SEK206) is trading below our estimate of fair value (SEK318.75)

Significantly Below Fair Value: 0MR5 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0MR5?

Key metric: As 0MR5 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0MR5. This is calculated by dividing 0MR5's market cap by their current earnings.
What is 0MR5's PE Ratio?
PE Ratio33.3x
EarningsSEK 150.21m
Market CapSEK 5.00b

Price to Earnings Ratio vs Peers

How does 0MR5's PE Ratio compare to its peers?

The above table shows the PE ratio for 0MR5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.5x
NIOX NIOX Group
21.1x15.8%UK£232.4m
EKF EKF Diagnostics Holdings
25.2xn/aUK£120.2m
SN. Smith & Nephew
34.5x22.6%UK£8.6b
AMS Advanced Medical Solutions Group
37.3x20.5%UK£415.2m
0MR5 CellaVision
33.3x22.5%SEK 5.0b

Price-To-Earnings vs Peers: 0MR5 is expensive based on its Price-To-Earnings Ratio (33.3x) compared to the peer average (29.5x).

Price to Earnings Ratio vs Industry

How does 0MR5's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0MR5 33.3xIndustry Avg. 30.8xNo. of Companies9PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0MR5 is expensive based on its Price-To-Earnings Ratio (33.3x) compared to the European Medical Equipment industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 0MR5's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0MR5 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.3x
Fair PE Ratio33.6x

Price-To-Earnings vs Fair Ratio: 0MR5 is good value based on its Price-To-Earnings Ratio (33.3x) compared to the estimated Fair Price-To-Earnings Ratio (33.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0MR5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 206.00
SEK 267.50
+29.9%
5.5%SEK 290.00SEK 250.00n/a4
Jan ’26SEK 212.50
SEK 270.00
+27.1%
6.9%SEK 300.00SEK 250.00n/a4
Dec ’25SEK 216.50
SEK 270.00
+24.7%
6.9%SEK 300.00SEK 250.00n/a4
Nov ’25SEK 239.75
SEK 262.50
+9.5%
8.7%SEK 300.00SEK 240.00n/a4
Oct ’25SEK 294.75
SEK 260.50
-11.6%
11.1%SEK 310.00SEK 240.00n/a4
Sep ’25SEK 266.00
SEK 256.75
-3.5%
8.7%SEK 295.00SEK 240.00n/a4
Aug ’25SEK 260.50
SEK 255.50
-1.9%
9.2%SEK 295.00SEK 235.00n/a4
Jul ’25SEK 253.00
SEK 256.25
+1.3%
10.0%SEK 300.00SEK 235.00n/a4
Jun ’25SEK 263.00
SEK 257.50
-2.1%
9.6%SEK 300.00SEK 240.00n/a4
May ’25SEK 230.00
SEK 257.50
+12.0%
9.6%SEK 300.00SEK 240.00n/a4
Apr ’25SEK 239.02
SEK 256.25
+7.2%
9.9%SEK 300.00SEK 240.00n/a4
Mar ’25SEK 256.25
SEK 256.25
0%
9.9%SEK 300.00SEK 240.00n/a4
Feb ’25SEK 199.60
SEK 204.25
+2.3%
12.3%SEK 230.00SEK 165.00n/a4
Jan ’25SEK 212.00
SEK 191.75
-9.6%
11.2%SEK 222.00SEK 165.00SEK 212.504
Dec ’24SEK 176.17
SEK 191.75
+8.8%
11.2%SEK 222.00SEK 165.00SEK 216.504
Nov ’24SEK 137.63
SEK 200.50
+45.7%
7.4%SEK 222.00SEK 180.00SEK 239.754
Oct ’24SEK 160.00
SEK 220.00
+37.5%
8.5%SEK 250.00SEK 200.00SEK 294.754
Sep ’24SEK 197.80
SEK 220.00
+11.2%
8.5%SEK 250.00SEK 200.00SEK 266.004
Aug ’24SEK 218.00
SEK 220.00
+0.9%
8.5%SEK 250.00SEK 200.00SEK 260.504
Jul ’24SEK 184.20
SEK 197.50
+7.2%
11.9%SEK 220.00SEK 165.00SEK 253.004
Jun ’24SEK 203.00
SEK 197.50
-2.7%
11.9%SEK 220.00SEK 165.00SEK 263.004
May ’24SEK 175.00
SEK 222.50
+27.1%
20.1%SEK 280.00SEK 160.00SEK 230.004
Apr ’24SEK 184.86
SEK 247.50
+33.9%
11.1%SEK 280.00SEK 205.00SEK 239.024
Mar ’24SEK 201.50
SEK 250.00
+24.1%
9.5%SEK 280.00SEK 215.00SEK 256.254
Feb ’24SEK 248.99
SEK 260.00
+4.4%
4.7%SEK 275.00SEK 245.00SEK 199.603
Jan ’24SEK 232.50
SEK 260.00
+11.8%
4.7%SEK 275.00SEK 245.00SEK 212.003
Analyst Price Target
Consensus Narrative from 4 Analysts
SEK 263.03
Fair Value
21.7% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 16:11
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CellaVision AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sten GustafssonABG Sundal Collier
Bjorn RydellABG Sundal Collier Sponsored
Carl-Oscar BredengenBerenberg